Edwards Lifesciences price target raised to $71 from $66 at Canaccord

Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $71 from $66 and keeps a Hold rating on the shares. The firm said they delivered a solid Q4 and management reiterated guidance issued in December at the company’s investor day and provided Q1/25 guidance that, most notably, included total company and TAVR year-over-year growth rates below the low end of the FY25 expectations due to one less selling day in Q1/25.